LONDON, Nov. 28, 2022 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that management will host a soft talk at the Evercore ISI HealthCONx conference at 9:15 am ET on November 30, 2022.
A live audio webcast of the fireside chat will be accessible from the “Events” page of the Investors section of the COMPASS website. The webcast replay will be available for 30 days after the event. For more information please visit go.compasspathways.com.
About COMPASS Pathways
COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is to improve the lives of those who suffer from mental health problems and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is delivered in conjunction with psychological support. COMP360 has been designated an Innovative Therapy by the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD). We have completed a phase 2b clinical trial of psilocybin therapy for TRD at 22 sites in Europe and North America and are preparing to begin a phase 3 program by the end of 2022. This phase 2b trial was the largest randomized , controlled and double. blinded clinical trial of psilocybin therapy ever conducted, and our primary data showed a statistically significant (p<0.001) and clinically relevant improvement in the severity of depressive symptoms after three weeks for patients receiving a single high dose of psilocybin COMP360 with psychological support. We are also running Phase 2 clinical trials of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD) and anorexia nervosa. COMPASS is headquartered in London, UK, with offices in New York and San Francisco in the US. Our vision is a world of mental wellbeing. www.compasspathways.com
Availability of Other Information About COMPASS Pathways
Investors and others should note that we communicate with our investors and the public through our website (www.compasspathways.com), our investor relations website (ir.compasspathways.com), and on social media. (LinkedIn), including, but not limited to, investor presentations and investor fact sheets, US Securities and Exchange Commission filings, press releases, public conference calls, and webcasts. The information we post on these channels and websites may be considered material information. As a result, we encourage investors, the media and others interested in us to periodically review the information that is posted on these channels, including the investor relations website. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The content of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed to be incorporated by reference in any file under the Securities Act 1933.
inquiries
Media: Amy Lawrence, [email protected], +44 7813 777 919
Investors: Stephen Schultz, [email protected], +1 401 290 7324
